490,000 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Senator Investment Group LP

Senator Investment Group LP acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 490,000 shares of the medical research company’s stock, valued at approximately $36,275,000. Senator Investment Group LP owned approximately 0.08% of Edwards Lifesciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of EW. Vanguard Group Inc. grew its holdings in Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 5.3% during the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock valued at $2,458,601,000 after acquiring an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock valued at $1,007,520,000 after purchasing an additional 126,194 shares in the last quarter. Fisher Asset Management LLC increased its position in Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after purchasing an additional 696,965 shares during the last quarter. Finally, Norges Bank purchased a new stake in Edwards Lifesciences during the fourth quarter valued at $610,895,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.5 %

Shares of Edwards Lifesciences stock opened at $71.56 on Monday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market cap of $42.07 billion, a price-to-earnings ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.15. The firm’s 50-day moving average is $71.31 and its two-hundred day moving average is $70.92.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on EW. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. Truist Financial dropped their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a report on Friday, April 11th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $78.55.

Insider Activity

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. This represents a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,853 shares of company stock worth $5,163,062. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.